Multiple Sclerosis and Neuroimmunology Clinical Trials
Project BIG: The Stanford Brain Immune Gut Research Initiative
PI: Jeffrey Dunn, MD
Research Coordinator: Julia Sumera, neuroimmunologyresearch@stanford.edu
Status: Enrolling
A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
NCT06138132
PI: Jeffrey Dunn, MD
Research Coordinator: Emma Martinez, neuroimmunologyresearch@stanford.edu
Status: Enrolling
A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (BEAT-MS)
NCT04047628
PI: Jeffrey Dunn, MD
Research Coordinator: Crystal Ton-Nu, neuroimmunologyresearch@stanford.edu
Status: Enrolling
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study with an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanlixizumab in Adult Participants with Myelin Oligodentrocyte Glycoprotein (MOG) antibody-associated disease (MOG-AD) (cosMOG)
NCT05063162
PI: Christopher Lock, MD
Research Coordinator: Tara Sarkar, neuroimmunologyresearch@stanford.edu
Status: Enrolling
A Phase 3 randomized, double-blind, efficacy and safety study comparing frexalimab (SAR441344) to placebo in adult participants with Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)
NCT06141486
PI: Christopher Lock, MD
Research Coordinator: Jennifer Cuevas, neuroimmunologyresearch@stanford.edu
Status: Enrolling
CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT04886492
PI: Christopher Lock, MD
Research Coordinator: Tara Sarkar, neuroimmunologyresearch@stanford.edu
Status: Enrolling
Ozanimod (Zeposia) in Multiple Sclerosis and Ulcerative Colitis: High Dimensional Immunometabolomic Analysis of Immune Cell Subsets with CyToF, CITE-seq, and Multiparameter Flow Cytometry In Treated Individuals Compared with Baseline.
PI: Lawrence Steinman MD
Research Coordinator: Julia Sumera, neuroimmunologyresearch@stanford.edu
Status: Enrolling
Retinal Biomarkers of Inflammation and Degeneration in Multiple Sclerosis
PI: Heather Moss, MD
Research Coordinator: Tara Sarkar, neuroimmunologyresearch@stanford.edu
Status: Enrolling